124 related articles for article (PubMed ID: 9523991)
1. Lipoamino acid conjugates of methotrexate with antitumor activity.
Pignatello R; Jansen G; Kathmann I; Puglisi G; Toth I
J Pharm Sci; 1998 Mar; 87(3):367-71. PubMed ID: 9523991
[TBL] [Abstract][Full Text] [Related]
2. Lipophilic methotrexate conjugates with antitumor activity.
Pignatello R; Spampinato G; Sorrenti V; Di Giacomo C; Vicari L; McGuire JJ; Russell CA; Puglisi G; Toth I
Eur J Pharm Sci; 2000 May; 10(3):237-45. PubMed ID: 10767601
[TBL] [Abstract][Full Text] [Related]
3. Lipophilic conjugates of methotrexate with short-chain alkylamino acids as DHFR inhibitors. Synthesis, biological evaluation, and molecular modeling.
Pignatello R; Guccione S; Forte S; Di Giacomo C; Sorrenti V; Vicari L; Uccello Barretta G; Balzano F; Puglisi G
Bioorg Med Chem; 2004 Jun; 12(11):2951-64. PubMed ID: 15142554
[TBL] [Abstract][Full Text] [Related]
4. Cytotoxic effects of folate antagonists against methotrexate-resistant human leukemic lymphoblast CCRF-CEM cell lines.
Mini E; Moroson BA; Franco CT; Bertino JR
Cancer Res; 1985 Jan; 45(1):325-30. PubMed ID: 3855284
[TBL] [Abstract][Full Text] [Related]
5. Analogues of N alpha-(4-amino-4-deoxypteroyl)-N delta-hemiphthaloyl-L-ornithine (PT523) modified in the side chain: synthesis and biological evaluation.
Rosowsky A; Vaidya CM; Bader H; Wright JE; Teicher BA
J Med Chem; 1997 Jan; 40(3):286-99. PubMed ID: 9022795
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological activity of folic acid and methotrexate analogues containing L-threo-(2S,4S)-4-fluoroglutamic acid and DL-3,3-difluoroglutamic acid.
Hart BP; Haile WH; Licato NJ; Bolanowska WE; McGuire JJ; Coward JK
J Med Chem; 1996 Jan; 39(1):56-65. PubMed ID: 8568827
[TBL] [Abstract][Full Text] [Related]
7. Dihydrofolate reductase binding and cellular uptake of nonpolyglutamatable antifolates: correlates of cytotoxicity toward methotrexate-sensitive and -resistant human head and neck squamous carcinoma cells.
Chen G; Wright JE; Rosowsky A
Mol Pharmacol; 1995 Oct; 48(4):758-65. PubMed ID: 7476904
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and preliminary in vitro screening of lipophilic alpha, gamma-bis(amides) as potential prodrugs of methotrexate.
Pignatello R; Sorrenti V; Spampinato G; Pecora T; Panico A; Di Giacomo C; Fresta M; Vanella A; Puglisi G
Anticancer Drug Des; 1996 Apr; 11(3):253-64. PubMed ID: 8663912
[TBL] [Abstract][Full Text] [Related]
9. A new analogue of 10-deazaaminopterin with markedly enhanced curative effects against human tumor xenografts in mice.
Sirotnak FM; DeGraw JI; Colwell WT; Piper JR
Cancer Chemother Pharmacol; 1998; 42(4):313-8. PubMed ID: 9744777
[TBL] [Abstract][Full Text] [Related]
10. Novel 5-substituted, 2,4-diaminofuro[2,3-d]pyrimidines as multireceptor tyrosine kinase and dihydrofolate reductase inhibitors with antiangiogenic and antitumor activity.
Gangjee A; Zeng Y; Ihnat M; Warnke LA; Green DW; Kisliuk RL; Lin FT
Bioorg Med Chem; 2005 Sep; 13(18):5475-91. PubMed ID: 16039863
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, dihydrofolate reductase inhibition, antitumor testing, and molecular modeling study of some new 4(3H)-quinazolinone analogs.
Al-Rashood ST; Aboldahab IA; Nagi MN; Abouzeid LA; Abdel-Aziz AA; Abdel-Hamide SG; Youssef KM; Al-Obaid AM; El-Subbagh HI
Bioorg Med Chem; 2006 Dec; 14(24):8608-21. PubMed ID: 16971132
[TBL] [Abstract][Full Text] [Related]
12. The molecular perspective: methotrexate.
Goodsell DS
Stem Cells; 1999; 17(5):314-5. PubMed ID: 10527466
[No Abstract] [Full Text] [Related]
13. Engineering small molecule specificity in nearly identical cellular environments.
Sellmyer MA; Stankunas K; Briesewitz R; Crabtree GR; Wandless TJ
Bioorg Med Chem Lett; 2007 May; 17(10):2703-5. PubMed ID: 17383876
[TBL] [Abstract][Full Text] [Related]
14. Regiospecific gamma-conjugation of methotrexate to poly(L-lysine). Chemical and biological studies.
Rosowsky A; Forsch RA; Galivan J; Susten SS; Freisheim JH
Mol Pharmacol; 1985 Jan; 27(1):141-7. PubMed ID: 3965926
[TBL] [Abstract][Full Text] [Related]
15. Rational modification of the lead molecule: Enhancement in the anticancer and dihydrofolate reductase inhibitory activity.
Kaur J; Kaur S; Singh P
Bioorg Med Chem Lett; 2016 Apr; 26(8):1936-40. PubMed ID: 26979156
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological evaluation of 2,4-diamino-6-(arylaminomethyl)pyrido[2,3-d]pyrimidines as inhibitors of Pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase and as antiopportunistic infection and antitumor agents.
Gangjee A; Adair OO; Queener SF
J Med Chem; 2003 Nov; 46(23):5074-82. PubMed ID: 14584957
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and antitumor evaluation of novel pyrazolo[3,4-
Salem IM; Mostafa SM; Salama I; El-Sabbagh OI; Hegazy WAH; Ibrahim TS
J Enzyme Inhib Med Chem; 2023 Dec; 38(1):203-215. PubMed ID: 36382444
[TBL] [Abstract][Full Text] [Related]
18. Mechanism inspired development of rationally designed dihydrofolate reductase inhibitors as anticancer agents.
Singh P; Kaur M; Sachdeva S
J Med Chem; 2012 Jul; 55(14):6381-90. PubMed ID: 22734697
[TBL] [Abstract][Full Text] [Related]
19. Dendrimer-based multivalent methotrexates as dual acting nanoconjugates for cancer cell targeting.
Li MH; Choi SK; Thomas TP; Desai A; Lee KH; Kotlyar A; Banaszak Holl MM; Baker JR
Eur J Med Chem; 2012 Jan; 47(1):560-72. PubMed ID: 22142685
[TBL] [Abstract][Full Text] [Related]
20. Dihydrofolate reductase mutant with exceptional resistance to methotrexate but not to trimetrexate.
Pineda P; Kanter A; McIvor RS; Benkovic SJ; Rosowsky A; Wagner CR
J Med Chem; 2003 Jul; 46(14):2816-8. PubMed ID: 12825924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
